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Introduction {#sec004}
============

Chikungunya virus (CHIKV) is an important but often overlooked cause of fever in tropical and sub-tropical regions. It sometimes co-circulates with dengue virus (DENV), as both pathogens share the *Aedes* mosquito vector \[[@pntd.0008355.ref001],[@pntd.0008355.ref002]\]. Unlike dengue fever, which is widely recognized in Indonesia, CHIKV infection remains significantly underdiagnosed \[[@pntd.0008355.ref003]\]. Overlapping clinical presentations of DENV, CHIKV and other endemic infections \[[@pntd.0008355.ref004]\] as well as lack of CHIKV testing capacity \[[@pntd.0008355.ref005]\] contribute to underdiagnoses of CHIKV.

Previous reports from the Indonesian Ministry of Health (MOH) have identified multiple CHIKV outbreaks \[[@pntd.0008355.ref006]--[@pntd.0008355.ref008]\]. After a hiatus of 16 years, chikungunya outbreaks occurred in 24 areas throughout Indonesia from 2001--2003 \[[@pntd.0008355.ref008]\]. In 2009 and 2010, chikungunya outbreaks hit West and Central Indonesia, and cases rose from approximately 3,000 per year to 83,000 and 52,000 cases per year respectively \[[@pntd.0008355.ref006]\]. After 2010, detected cases fell to 3,000 per year. Except during outbreaks, the incidence rate is likely an underestimate since diagnosis is often based solely on clinical presentation \[[@pntd.0008355.ref009],[@pntd.0008355.ref010]\].

Given the endemicity of CHIKV in Indonesia, a better understanding of CHIKV epidemiology, clinical course, and diagnostic approaches is needed. To address this need, we evaluated demographic, clinical, and laboratory data from patients hospitalized with fever as part of a multi-site observational study conducted in Indonesia.

Materials and Methods {#sec005}
=====================

Study design and population {#sec006}
---------------------------

Subjects were identified from an observational study of febrile illness \[[@pntd.0008355.ref011]\] conducted by the Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) \[[@pntd.0008355.ref012]\] from July 2013 to June 2016. The study recruited patients ≥1-year-old presenting to one of eight hospitals across Indonesia with acute fever and no history of hospitalization in the past three months. Demographic and clinical information were collected at enrollment; biological specimens were collected at enrollment, once 14 to 28 days after enrollment, and three months after enrollment.

Specimen screening and testing flow {#sec007}
-----------------------------------

Blood was collected and processed at study sites and then shipped to INA-RESPOND laboratory. All plasma samples were first screened for DENV infection by Dengue IgM capture/IgG indirect assays, NS1 antigen ELISA (Focus Diagnostics, CA, USA) and/or multiplex semi-nested reverse transcriptase PCR \[[@pntd.0008355.ref013]\]. Specimens negative for DENV infection and a subset specimen from confirmed DENV cases were then screened for acute CHIKV infection (ACI). First, convalescent (3-month) plasma samples were screened by CHIKV IgG ELISA (Euroimmun Ag, Lubeck, Germany). If positive, paired acute and convalescent samples were tested simultaneously by CHIKV IgG/IgM ELISA (Euroimmun Ag, Lubeck, Germany), and acute plasma samples were further tested by real-time reverse transcriptase PCR (rRT-PCR) \[[@pntd.0008355.ref014]\]. Acute plasma from subjects without convalescent specimens were tested by CHIKV IgM/IgG ELISA and rRT-PCR.

CHIKV serology {#sec008}
--------------

Serological testing was performed using anti-CHIKV IgG and IgM ELISA systems according to manufacturer's instructions. Each test used 6 μL of plasma in a 1:100 dilution. Results were read by a microtiter plate reader at 450 nm within 30 minutes of test completion. Samples were considered positive if the optical density (OD) ratio (index) between the sample and calibrator control was ≥1.1.

CHIKV RT-PCR {#sec009}
------------

### Viral RNA Extraction and RT-PCR {#sec010}

CHIKV RNA was extracted from plasma using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. RNA was eluted in 60 μL and stored at -80°C until use. The rRT-PCR assay used to detect CHIKV has been previously described \[[@pntd.0008355.ref003]\]. Briefly, a segment in the nonstructural gene of CHIKV was amplified using primers CHIKV-6856 (TCACTCCCTGTTGGACTTGATAGA) and CHIKV-6981 (TTGACGAACAGAGTTAGGAACATACC) and QuantiTect Probe RT-PCR Kit (Qiagen, Hlden, Germany), and detected with the probe CHIKV-6919 (3\'-FAM-AGGTACGCGCTTCAAGTTCGGCG-BHQ1-5\'). The 20 μL reaction mixture consists of 1X QuantiTect Probe RT-PCR Master Mix, 1 μM primers, 0.25 μM probe, 0.25 μL RT-Mix, and 4 μL of extracted CHIKV RNA. The positive control was CHIKV RNA extracted from a CHIKV culture. rRT-PCR was run on the Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific, MA, USA) with cycling conditions consisting of reverse transcription at 50°C for 20 minutes, an initial denaturation at 95°C for 15 minutes, and 40 cycles at 95°C for 15 seconds and 60°C for 60 seconds.

### Genomic sequencing and phylogenetic analysis {#sec011}

Specimens positive by CHIKV rRT-PCR were sequenced at the E1 gene \[[@pntd.0008355.ref003]\]. Viral RNA was first converted into complementary DNA using the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, CA, USA), and amplified at a region covering the E1 gene using the Platinum Taq DNA Polymerase High Fidelity (Invitrogen, CA, USA) and primer pairs 9870F/10710R and 10378F/11359R. Phylogenetic analysis was done using the maximum likelihood method in the Molecular Evolutionary Genetics Analysis version 7 (MEGA 7.0.20) package. The nucleotide substitution model TN93+G best described the sequence evolution. The strength of tree topology was estimated by bootstrap analysis using 1000 replicates. Trees were unrooted.

### Definition for CHIKV diagnosis classification {#sec012}

Patients were considered to have ACI when CHIKV RNA was detected by rRT-PCR, sero-conversion occurred or four-fold increase in OD ratio (index) of IgM and IgG between paired samples was observed. Possible secondary ACI was inferred when the above criteria was met and IgG was detected in acute specimens. Probable ACI was inferred when only CHIKV IgM was detected in the acute specimen, but increased index could not be confirmed due to lack of convalescent specimen. Probable ACI with possible secondary infection was inferred when RT-PCR was negative, and IgM sero-converted but OD in acute and convalescent specimens was equivalent. Recent CHIKV infection (RCI) was inferred when CHIKV RNA was not detected, but high index (\>3) of IgM in acute specimens decreased in convalescent specimens. Non-CHIKV infection with persistent IgM was ascribed when CHIKV RNA was negative, but low index IgM and IgG was detected in acute and convalescent plasma.

Statistical analysis {#sec013}
--------------------

Data were collected in OpenClinica v.3.1 (OpenClinica, LLC) and analyzed using STATA v.15.1 (StataCorp LLC). Proportions were compared between groups using the chi-square test. The t-test was used to compare means between groups. Correlation between variables was assessed using the Spearman correlation test.

Ethics {#sec014}
------

All subjects or their legal guardians gave their written informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the IRBs of Faculty of Medicine University of Indonesia/ Dr. Cipto Mangunkusumo Hospital (451/PT02.FK/ETIK/2012), Dr. Soetomo Hospital (192/Panke.KKE/VIII/2012), and the National Institute of Health and Research and Development (NIHRD), Ministry of Health, Indonesia (KE.01.05/EC/407/2012).

Results {#sec015}
=======

Epidemiology {#sec016}
------------

1,486 subjects were enrolled in the parent AFIRE study \[[@pntd.0008355.ref015]\]; 1,464 of those subjects had adequate specimens to be included in this study. One CHIKV case was suspected by site clinicians based on a positive rapid IgM test. However, IgM/IgG ELISA or rRT-PCR at the INA-RESPOND laboratory was negative and *Rickettsia typhi* infection was later confirmed. The remaining 1,463 subjects were screened for DENV, of which 468 (32%) were positive \[[@pntd.0008355.ref016]\]. 105 of 468 randomly selected specimens from confirmed DENV cases were then screened for ACI. Among the DENV-negative subjects, 12 were excluded due to a lack of adequate specimens, and 983 were screened for CHIKV by IgM/IgG ELISA and/or rRT-PCR. Evidence of ACI was found in 40/1,089 (3.7%) subjects, all of whom were DENV-negative. The screening algorithm and specimen flow is shown in ([Fig 1](#pntd.0008355.g001){ref-type="fig"}).

![Study algorithm to identify acute chikungunya infection.\
\*DENV IgM/IgG, NS1, RT-PCR; \*\* CHIKV IgM/IgG, RT-PCR.](pntd.0008355.g001){#pntd.0008355.g001}

The distribution of acute and prior CHIKV infections across sites is shown in ([Fig 2](#pntd.0008355.g002){ref-type="fig"}). ACI was most prevalent in Makassar (7%), followed closely by Semarang (5.2%). Prior CHIKV exposure, determined by IgG serology, was also highest (37.9% and 45.9%, respectively) in these two cities ([Table 1](#pntd.0008355.t001){ref-type="table"}). In Jakarta and Denpasar where the prevalence of prior CHIKV exposure was low (25.2% and 28.5%, respectively), ACI was not detected. Previous exposure was significantly correlated with age group (P\<0.01). CHIK cases were identified in Indonesia during every study year, though temporal distribution at sites varied ([Fig 3](#pntd.0008355.g003){ref-type="fig"}).

![The distribution of Chikungunya virus exposure in Indonesia.\
*Acute CHIKV infection (ACI)*: CHIKV RNA was detected by rRT-PCR and/or sero-conversion or four-fold increase in OD ratio of IgM and IgG between paired samples was observed; *Previous infection*: no evidence of ACI, IgG was positive in acute specimens; *No exposure of CHIKV*: IgG was negative in convalescent specimens. Map source Wikimedia Commons Atlas of the World *\[Atlas of Indonesia\]*. Available from: <https://commons.wikimedia.org/wiki/Atlas_of_Indonesia#/media/File:Map_of_Indonesia_Demis.png> \[Accessed 21 October 2019\].](pntd.0008355.g002){#pntd.0008355.g002}

![Distribution of acute chikungunya infection cases by month and year.](pntd.0008355.g003){#pntd.0008355.g003}

10.1371/journal.pntd.0008355.t001

###### Evidence of prior CHIKV exposure based on IgG sero-positivity by site and age.

![](pntd.0008355.t001){#pntd.0008355.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Site                                                 Age groups\                                                                                            
                                                       Total IgG positive/total tested (%)                                                                    
  ---------------------------------------------------- ------------------------------------- --------------- ---------------- ---------------- -------------- ------------------
  **Bandung**                                          2/34 (5.9)                            20/62 (32.3)    25/68 (36.8)     11/30 (36.7)     12/21 (57.1)   70/215 (32.5)

  **Denpasar**                                         0/5 (0)                               1/11 (9.1)      19/75 (25.3)     13/28 (46.4)     2/4 (50.0)     35/123 (28.5)

  **Jakarta**                                          3/30 (10)                             6/28 (21.4)     9/24 (37.5)      6/14 (42.9)      2/7 (28.6)     26/103 (25.2)

  **Makassar**                                         0/10 (0)                              2/26 (7.7)      33/79 (41.8)     15/23 (65.2)     3/4 (75)       53/142 (37.3)

  **Semarang**                                         5/34 (14.7)                           15/52 (28.8)    38/74 (51.4)     31/42 (73.8)     8/9 (88.9)     97/211 (45.9)

  **Surabaya**                                         1/14 (7.1)                            6/40 (15)       29/75 (38.7)     25/35 (71.4)     3/5 (60.0)     64/169 (37.9)

  **Yogyakarta**                                       6/41 (14.6)                           3/19 (15.8)     8/28 (28.6)      9/22 (40.9)      9/16 (56.3)    35/126 (27.8)

  **All sites**[\*](#t001fn001){ref-type="table-fn"}   17/168 (10.1)                         53/238 (22.3)   161/423 (38.1)   110/194 (56.7)   39/66 (59.1)   380/1,089 (34.9)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*CHIKV exposure is correlated with age group (p\<0.01). IgG sero-positivity based on IgG in baseline specimens.

Molecular and serological confirmation in each diagnosis group {#sec017}
--------------------------------------------------------------

### Acute CHIKV infections {#sec018}

Among 40 ACI, IgM/IgG sero-conversion plus presence of CHIKV RNA was observed in 36 subjects and IgM/IgG sero-conversion alone in 4 subjects. In 35/38 (92%) cases who had late convalescent specimens, IgM was still detected at 3 to 3.5 months after hospitalization. In 2 cases, IgG was also detected in acute specimens, suggesting possible secondary ACI. In 35 of the 36 subjects, rRT-PCR cycle threshold values were low (mean 29.4, range 19.5--39.0). In the other case, CHIKV RNA was detected using a gel-based RT-PCR method. All sequences of CHIKV E1 gene from 30 specimens across 5 study sites were closely related to CHIKV previously identified in Indonesia and belonged to the Asian CHIKV genotype ([Fig 4](#pntd.0008355.g004){ref-type="fig"}).

![Phylogenetic trees showing the relationship of Chikungunya virus identified in AFIRE study.\
The relationship was constructed by the maximum likelihood method using nucleotide sequences of the E1 gene (1320 bp) with 1000 bootstrap replicates. The trees consist of 30 E1 gene nucleotide sequences from AFIRE specimens and other sequences from GenBank database. The AFIRE specimens are shown in bold, in the following format: Subject Identification Number \| Country \| City \| Year. The sequences retrieved from GenBank are shown in the following format: Accession Number \| Strain (if available) \| Country \| City (if available) \| Year. The scale presents the number of nucleotide substitutions per site along the branches. The sequences of the AFIRE Chikungunya E1 gene were submitted to GenBank. The genotypes were inferred based on phylogenetic clustering set by authors referred for the analysis.](pntd.0008355.g004){#pntd.0008355.g004}

### Probable acute CHIKV infection {#sec019}

Two probable ACI cases with only acute specimens were negative by rRT-PCR, but IgM was detected (titers 1:100 and 1:400) without IgG. In two probable ACI with possible secondary infection cases, IgM sero-converted or increased (0.8 to 3, and 2.4 to 3.3) with high index or slightly increased IgG (3.2 to 3.2 and 2.8 to 3.3).

### Recent CHIKV infection {#sec020}

In one of the 983 non-dengue subjects, CHIKV IgM between acute and week-three specimens decreased from 4.6 to 2.4 while IgG slightly increased from 3.5 to 3.7, consistent with RCI. An RCI in a subject with dengue was also identified as CHIKV IgM index decreased from 5.9 to 4.7, and IgG index increased from 2.4 to 3.1 between acute and week-two specimens.

### Persistent CHIKV IgM {#sec021}

In the non-dengue group, low index CHIKV IgM in acute and convalescent specimens, with detectable CHIKV IgG was observed in 9 cases. Two of these cases with persistent IgM were later confirmed as Influenza A/H3N2 and Leptospirosis. In the dengue group, CHIKV IgM and IgG were detected in a DENV-3 infected subject who only had an acute specimen. In another case, low CHIKV IgM titers and high CHIKV IgG titers were detected in acute and convalescent specimens. As CHIKV rRT-PCR was negative, the latter two cases were considered dengue with persistent CHIKV IgM.

### Clinical presentations and laboratory examination {#sec022}

The 40 ACI subjects had a median age of 20 years (range 1--83 years). The distribution of positive cases by gender (0.67: 1.0, female: male) mirrored that of the parent AFIRE study (0.79: 1.0). Subjects presented to hospital 2--4 days after symptom onset and had a median temperature of 39°C. Nausea, vomiting, headache, arthralgias, and myalgias were the most common presenting symptoms. Convulsions were significantly more common in children, whereas arthralgias was significantly more common in adults ([S1 Table](#pntd.0008355.s002){ref-type="supplementary-material"}). Most patients had normal leukocyte (78%) and platelet (90%) counts at presentation. However, lymphopenia was slightly more frequent than normal lymphocyte counts \[19/35 (54.3%) vs 13/35 (37.1%)\]. Hematology profiles were not significantly different between pediatric and adult subjects ([S1 Table](#pntd.0008355.s002){ref-type="supplementary-material"}). Presenting features and clinical laboratory findings are detailed in ([Table 2](#pntd.0008355.t002){ref-type="table"}).

10.1371/journal.pntd.0008355.t002

###### Presenting features of 40 laboratory-confirmed cases of acute CHIKV infection.

![](pntd.0008355.t002){#pntd.0008355.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                               Total             Clinical Diagnosis at sites                                                                                                                                                                                                                       
  ---------------------------------------------------------------------------- ----------------- ---------------------------------------------- ---------------------------------------------- --------------------- -------------------------- ----------------------------------- -------------------- --------------------- ------------------- -------------------
  **Demographics **                                                                                                                                                                                                                                                                                                                                

  Age, median (range) year                                                     20.4 (1--83.1)    15.8 (1.4--71.4)                               22.3 (2.2--39.8)                               37.2                  3.5 (1--16.3)              14.4 (4.9--83.1)                    26.3 (23.1--56.1)    16.1                  40 (25--56)         10.8 (1.5--20.1)

  Female, N (%)                                                                16 (40)           4 (36.4)                                       4 (50)                                         0                     2 (33.3)                   3 (60)                              0                    1                     0                   2 (100)

  **Fever**                                                                                                                                                                                                                                                                                                                                        

  Days ill, median (IQR)                                                       2 (1--6)          2 (1--4)                                       2 (1--6)                                       6                     2 (1--4)                   2 (2--5)                            3 (2--5)             5                     1.5 (1--2)          1.5 (1--2)

  Temperature (°C), median (IQR)                                               38.9 (36--41.2)   39.2 (37.2--39.9)                              38.5\                                          39.5                  39.1 (38.5--39.8)          38.7 (38--40)                       38.7 (37.5--39.4)    38.2                  40.1 (39.1--41.2)   37.6 (37--38.2)
                                                                                                                                                (36--39.8)                                                                                                                                                                                         

  **Symptoms, N (%)**                                                                                                                                                                                                                                                                                                                              

  General symptoms                                                                                                                                                                                                                                                                                                                                  

  Anorexia                                                                     10 (25)           4 (36.4)                                       1 (12.5)                                       1                     0                          2 (40)                              0                    1                     0                   1 (50)

  Chills                                                                       9 (22.5)          1 (9.1)                                        3 (37.5)                                       1                     2 (33.3)                   0                                   0                    1                     0                   1 (50)

  Lethargy                                                                     10 (25)           2 (18.2)                                       1 (12.5)                                       1                     1 (16.7)                   1 (20)                              2 (50)               1                     1 (50)              0

  Headache                                                                     18 (45)           5 (45.5)                                       4 (50)                                         0                     2 (33.3)                   1 (20)                              4 (100)              1                     1 (50)              0

  Neurological                                                                                                                                                                                                                                                                                                                                      

  Convulsion                                                                   5 (12.5)          1 (9.1)                                        0                                              0                     4 (66.7)                   0                                   0                    0                     0                   0

  Decrease of consciousness                                                    1 (2.5)           0                                              0                                              0                     0                          0                                   0                    0                     1 (50)              0

  Respiratory                                                                                                                                                                                                                                                                                                                                       

  Cough                                                                        9 (22.5)          5 (45.5)                                       0                                              0                     2 (33.3)                   2 (40)                              0                    0                     0                   0

  Haemoptysis                                                                  1 (2.5)           1 (9.1)                                        0                                              0                     0                          0                                   0                    0                     0                   0

  Runny nose                                                                   2 (5)             0                                              0                                              0                     2 (33.3)                   0                                   0                    0                     0                   0

  Epistaxis                                                                    2 (5)             1 (9.1)                                        0                                              0                     1 (16.7)                   0                                   0                    0                     0                   0

  Shortness of Breath                                                          3 (7.5)           0                                              0                                              0                     0                          2 (40)                              0                    1                     0                   0

  Gastrointestinal                                                                                                                                                                                                                                                                                                                                  

  Diarrhea                                                                     5 (12.5)          2 (18.2)                                       0                                              0                     0                          1 (20)                              0                    0                     2 (100)             0

  Nausea                                                                       26 (65)           8 (72.7)                                       6 (75)                                         1                     2 (33.3)                   3 (60)                              3 (75)               1                     2 (100)             0

  Vomiting                                                                     14 (35)           5 (45.5)                                       2 (25)                                         0                     1 (16.7)                   4 (80)                              1 (25)               0                     1 (50)              0

  Epigastric Pain                                                              5 (12.5)          2 (18.2)                                       1 (12.5)                                       0                     0                          0                                   2 (50)               0                     0                   0

  Musculoskeletal                                                                                                                                                                                                                                                                                                                                   

  Arthralgia                                                                   18 (45)           5 (45.5)                                       4 (50)                                         1                     0                          2 (40)                              4 (100)              1                     0                   1 (50)

  Myalgia                                                                      12 (30)           4 (36.4)                                       2 (25)                                         1                     1 (16.7)                   0                                   3 (75)               1                     0                   0

  Skin rash                                                                    6 (15)            0                                              1 (12.5)                                       0                     1 (16.7)                   1 (20)                              1 (25)               0                     0                   2 (100)

  Petechiae/ ecchymosis                                                        4 (10)            1 (9.1)                                        0                                              1                     1 (16.7)                   1 (20)                              0                    0                     0                   0

  **Laboratory findings, N (%)**                                                                                                                                                                                                                                                                                                                   

  Leukocytes[\*](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                   

  Leukopenia                                                                   4 (10)            2 (18.2)                                       1 (12.5)                                       1                     0                          0                                   0                    0                     0                   0

  Normal                                                                       31 (77.5)         8 (72.7)                                       6 (75)                                         0                     5 (83.3)                   5 (100)                             4 (100)              1                     0                   2 (100)

  Leukocytosis                                                                 5 (12.5)          1 (9.1)                                        1 (12.5)                                       0                     1 (16.7)                                                       0                    0                     2 (100)             0

  Lymphopenia                                                                  19/35 (54.3)      8 (72.7)                                       3/6 (50)                                       0                     3/5 (60)                   3/4 (75)                            0                    0                     2 (100)             0

  Normal lymphocytes                                                           13/35 (37.1)      3 (27.3)                                       3/6 (50)                                       0                     2/5 (40)                   0                                   3/4 (75)             1                     0                   1 (50)

  Lymphocytosis                                                                3/35 (7.5)        0                                              0                                              0                     0                          1/4 (25)                            1/4 (25)             0                     0                   1 (50)

  Platelets                                                                                                                                                                                                                                                                                                                                         

  Normal thrombocytes[\*](#t002fn001){ref-type="table-fn"}                     36 (90)           11 (100)                                       6 (75)                                         1                     6 (100)                    5 (100)                             2 (50)               1                     2 (100)             2 (100)

  Thrombocytopenia (≤150,000/mm^3^)                                            4 (10)            0                                              2 (25)                                         0                     0                          0                                   2 (50)               0                     0                   0

  **Treatment, N**                                                                                                                                                                                                                                                                                                                                 

  Antimicrobial                                                                21                4                                              6                                              1                     3                          4                                   0                    1                     1                   1

                                                                                                 Amoxicillin\                                   Ceftriaxone (4)\                               Ceftriaxone           Amoxicillin (2)\           Ampicillin\                         \-                   Cefotaxime            Ciprofloxacin       Ceftriaxone
                                                                                                 Chloramphenicol\                               Cefixime Amoxicillin                                                 Ampicillin                 Cefixime\                                                                                          
                                                                                                 Ceftriaxon\                                                                                                                                    Ceftriaxone\                                                                                       
                                                                                                 Cotrimoxazole                                                                                                                                  Levofloxacin                                                                                       

  **Outcomes**, **N (%)**                                                                                                                                                                                                                                                                                                                          

  Cured[\*\*](#t002fn002){ref-type="table-fn"}                                 31 (77.5)         10 (90.9)                                      7 (87.5)                                       1                     5 (83.3)                   4 (80)                              1 (25)               1                     2 (100)             0

  Cured with sequelae[\*\*\*](#t002fn003){ref-type="table-fn"}                 9 (22.5)          1 (9.1)                                        1 (12.5)                                       0                     1 (16.7)                   1 (20)                              3 (75)               0                     0                   2 (100)

  Death before discharge                                                       0                 0                                              0                                              0                     0                          0                                   0                    0                     0                   0

                                                                                                                                                                                                                                                                                                                                                    

  Underlying disease                                                            6                1\                                             1\                                             0                     0                          2\                                  0                    1\                    1\                  0
                                                                                                 Malnutrition                                   Hypertension                                                                                    CAD & Hypertension (1)\                                  Heart Septal Defect   Lung TB             
                                                                                                                                                                                                                                                Hypertension & Osteoarthritis (1)                                                                  

  Diagnostic standard of care test at the hospitals (positive/number tested)                     RDT Den NS1 (0/6)\                             RDT Den NS1 (0/3)\                             RDT Den IgM (0/1)\    RDT Den NS1 (0/1)\         RDT Den NS1 (0/2)\                  RDT Den NS1 (0/2)\   Not done              Note done           RDT Den NS1 (0/1)
                                                                                                 RDT Den IgM (1/7)\                             RDT Den IgM (0/4)\                             RDT Lepto IgM (0/1)   RDT Den IgM (0/1)\         RDT Salmonella IgM (0/1)            RDT Den IgM (0/1)                                              
                                                                                                 RDT Salmonella IgM (0/2) RDT Lepto IgM (0/1)   RDT Salmonella IgM (4/8) RDT Lepto IgM (0/1)                         RDT Salmonella IgM (0/1)                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted by age

\*\*Cured: original illness is no longer present

\*\*\* Sequelae: Lethargy, myalgia

None of the 40 ACI cases were accurately diagnosed by study site clinicians. Eleven subjects were misdiagnosed with DENV, two of whom had leukopenia, and all of whom presented with normal platelet counts. All were tested for DENV IgM or DENV NS1 antigen, and only one case was rapid IgM positive, which was later confirmed negative by ELISA. Eight subjects were misdiagnosed with typhoid fever following a positive (score ≥4) S. *typhi* IgM using the TUBEX TF, which was negative by ELISA. One subject was misdiagnosed with leptospirosis despite testing negative for *Leptospira spp* IgM. In these 20 cases, molecular and serological tests for suspected pathogens were all negative.

The remaining 20 subjects were diagnosed with unspecified fever (6), respiratory infection (5), non-specific viral infections (4), fever with rash (2), enteritis (2), and endocarditis (1) ([Table 2](#pntd.0008355.t002){ref-type="table"}). In 3 of the 6 unspecified fever cases, dengue or S. *typhi* rapid test was negative. No rapid diagnostic test was done in two elderly patients with suspected lower respiratory infections who had underlying diseases (coronary artery disease and hypertension, and hypertension and osteoarthritis). Rapid dengue or S. *typhi* tests were done in all the 3 cases with upper respiratory tract infection (URTI), and in 3 of 4 with suspected viral infection. All results were negative. One subject with a cardiac septal defect was suspected of having endocarditis, but blood culture was negative. One of the two diarrhea cases showed decreased consciousness, but no myalgia or arthralgia. Two cases presented with rash, one with cellulitis and severe arthralgia, and the other one was a 2-year-old girl with exanthema subitum. All the clinical and laboratory data are described in detail in ([Table 2](#pntd.0008355.t002){ref-type="table"}).

Discussion {#sec023}
==========

This study reveals important clinical and epidemiologic information about CHIKV in Indonesia. First, CHIKV is an important cause of fever amongst hospitalized patients, but is overlooked by clinicians. Second, prior exposure to CHIKV is high across Indonesian cities and correlates with age. Third, possible secondary ACI may occur. Lastly, all evaluated CHIKV belonged to Asian genotype.

CHIKV was the sixth most frequent pathogen identified in the parent AFIRE study, after DENV (32%), *Salmonella spp*. (6.9%), *Rickettsia spp*. (6.9%), influenza virus (4.6%), and leptospirosis (3.3%) \[[@pntd.0008355.ref015]\]. The prevalence of CHIKV in our cohort (2.7%) is similar to that of southern Sri Lanka in 2007 (3%) \[[@pntd.0008355.ref017]\], higher than similar studies in Cambodia (0.6%) \[[@pntd.0008355.ref018]\], Thailand (1.1%) \[[@pntd.0008355.ref019]\] or Central Java (1.7%) \[[@pntd.0008355.ref020]\], but lower than India in 2012 (6%) \[[@pntd.0008355.ref021]\]. Variation in case rates may be affected by different detection methods. The India, Thailand and Central Java studies used ELISA IgM assays in acute specimens only, while Cambodia, Sri Lanka, and our studies used RT-PCR and paired acute and convalescent specimens with ELISA IgM/IgG \[[@pntd.0008355.ref017],[@pntd.0008355.ref018]\]. Evidence of IgM persistence for up to one year \[[@pntd.0008355.ref022]\] may confound the ability to distinguish between acute infection and past exposure, as reflected by the India study

CHIKV infection was not detected in subjects from Jakarta, where evidence of prior exposure was lowest. In Denpasar, which has a high endemic burden of DENV, absence of CHIKV cases in our cohort may be related to competition between these viruses in their vectors \[[@pntd.0008355.ref023]\], or CHIKV was not tested in a sufficient number of dengue confirmed cases (only 21 of 111 (19%) dengue cases from Denpasar, and 105 of 468 (22%) from all sites). However, in Jakarta, it is plausible that *A*. *aegypti* and *A*. *albopictus* control programs have reduced the vectors for both CHIKV and DENV. It is also possible that CHIKV and DENV cases were mild and therefore did not present to hospital.

Our study is the first to demonstrate the variation of CHIKV exposure across seven Indonesian cities. CHIKV exposure in our pediatric cohort was much lower than DENV exposure reported or in the AFIRE study \[[@pntd.0008355.ref016]\]; CHIKV and DENV exposure in children ≤5 years and \>5--18 years were 10.1% vs 40.2% and 22.3% vs 89%, respectively. This epidemiologic data will benefit public health and immunization programs.

An unexpected result of our study was that none of the 40 laboratory-confirmed cases of CHIKV were recognized by clinicians. This may be attributable to the initial non-specific clinical presentation of the disease, atypical presentations, co-morbidities confounding typical presentations or low clinician awareness.

CHIKV manifestations overlap with those of other endemic infections. Furthermore, CHIKV cases may be subclinical or without pathognomonic manifestations \[[@pntd.0008355.ref003], [@pntd.0008355.ref010]\]. Arthralgia, the most pathognomonic symptoms for chikungunya, was reported in only 45% of cases. Arthralgia may have been under reported because children may not reliably identify arthralgias and myalgias, as reflected in the lower percentage of children reporting arthralgia compared to adults (23.5% vs 60.9%). Skin rash, which may be difficult to see on patients with dark skin or with minimum light, was even lower (15%). Without the typical signs and symptoms and confounded by presence of non-specific symptoms such as sore throat and cough, clinicians made the diagnosis of undifferentiated fever, febrile convulsions, or URTI in 9 subjects. Also, CHIK may present atypically with diarrhea \[[@pntd.0008355.ref024]\] or decreased consciousness \[[@pntd.0008355.ref025]\]. These were present in 3 of our cases, which were misdiagnosed as enteritis and herpes simplex infection. Comorbidities with chronic diseases such as septal defect, osteoarthritis, or COPD may have led clinicians to suspect typical disease associated infections.

Lack of access to accurate rapid diagnostics, including bedside diagnostics, creates a challenge. Currently CHIKV IgM rapid diagnostics are plagued by low sensitivity. Performance is better for the Eat Central South African (ECSA) genotype, but suboptimal for the Asian genotype circulating in Indonesia \[[@pntd.0008355.ref026],[@pntd.0008355.ref027]\]. And since IgM is usually detectable 5 days after fever onset, utility of IgM in acute specimens is minimal. Additionally, persistence of IgM for CHIKV more than a year after infection \[[@pntd.0008355.ref003]\] may confound interpretation of positive results. Our study reflects these challenges as IgM, even when tested by a sensitive ELISA, was only detected in 10% of CHIK case acute specimens, and also in 11 non-CHIK cases. Furthermore, serological diagnosis requires assessment of titers in convalescent specimens, so has minimal value for acute treatment decisions. These challenges highlight the need for CHIKV RNA or antigen based rapid diagnostic testing to guide clinical decision making.

Availability of reliable point-of-care kits for other pathogens, such as dengue, malaria, or typhoid fever, help rule out those pathogens to narrow the differential. However, even these results should be interpreted cautiously. For example, rapid IgM S. *typhi* may persist \[[@pntd.0008355.ref028]\], which may explain why 8 laboratory-confirmed CHIKV cases were misdiagnosed as typhoid fever in our study. In the absence of accurate rapid diagnostics for CHIK, clinicians will continue to rely on knowledge of local epidemiology, clinical and hematologic data and available diagnostic test results. Exposure history is also helpful as clusters of CHIK are common \[[@pntd.0008355.ref029]--[@pntd.0008355.ref031]\]. Headache is often found, but less frequent and severe compared to dengue \[[@pntd.0008355.ref032]\]. Nausea and vomiting was less frequent than dengue, but arthralgia and rash are more frequent \[[@pntd.0008355.ref033]\]. Hematology parameters that can be used to distinguish with dengue are normal leukocyte and normal platelet count, whereas with S. *typhi* were normal leukocyte and lower lymphocyte counts \[[@pntd.0008355.ref033]\].

Differentiating between CHIKV and other infections is important for appropriate case management and anticipation of clinical course \[[@pntd.0008355.ref034]\]. Accurate diagnosis of CHIKV would reduce the unnecessary use of antimicrobials that would be administered if cases were misdiagnosed as typhoid fever, leptospirosis, rickettsiosis or influenza. In our study, more than half of the subjects received unnecessary antibiotics, increasing the risk for adverse events and generation of antibiotic resistance. Accurate diagnosis would also facilitate appropriate patient counseling especially in pregnant patients \[[@pntd.0008355.ref035],[@pntd.0008355.ref036]\].

The identification of two possible secondary ACI in Semarang and Surabaya support previous findings from Bandung \[[@pntd.0008355.ref003]\]. There are several plausible explanations. First, recovery from infection may not engender lifelong immunity. Second, development of CHIK IgG in these patients may have been faster than average. Third, cross-reactivity with other alphaviruses (Ross River virus, Eastern equine encephalitis virus, Barmah-Forest virus, Mayaro virus) \[[@pntd.0008355.ref037],[@pntd.0008355.ref038]\] is possible given that false positives have been reported with the IgG kit we employed when compared to an in-house ELISA assay used by the US-CDC in Panama \[[@pntd.0008355.ref039]\]. However, there were no reports of the circulating Ross river viruses or other alphaviruses in Indonesia, except in Moluccas, which was not a site in our study \[[@pntd.0008355.ref038],[@pntd.0008355.ref040]\]. Furthermore, a study in the Philippines, using the more specific PRNT assay, revealed that CHIK infection only occurred in 106 subjects who did not have CHIKV neutralizing antibodies in their acute samples \[[@pntd.0008355.ref041]\]. Finally, it is also possible that the strains causing the first and second infections were different, which may occur with circulation of both Asian and ECSA genotypes in Indonesia \[[@pntd.0008355.ref006]\]. All CHIKV in our study belonged to the Asian genotype, forming a clade with CHIKV identified in other parts of Indonesia \[[@pntd.0008355.ref003],[@pntd.0008355.ref009],[@pntd.0008355.ref042]\]. Viral genotype has been associated with illness severity, virulence, and transmissibility. The tendency toward milder disease with the Asian genotype compared to the ECSA genotype is consistent with our findings that only one third of patients had sequelae at 3 months and no fatalities occurred \[[@pntd.0008355.ref043]\].

This study has several limitations. As it was part of a larger study to identify etiologies of fever, CHIK specific questions such as those related to arthralgia were not asked. This study was conducted only in large Indonesian cities as opposed to throughout the archipelago, therefore results may not be generalizable to the entire population. Also, CHIKV and DENV co-infections might have been missed; to address this, we evaluated 22% of patients with DENV infection for CHIKV co-infection.

In conclusion, our study highlights the importance of considering CHIKV infection as a cause of acute fever requiring hospitalization in Indonesia. Clinicians must be aware of CHIKV's diverse clinical presentation. Improved recognition and diagnosis will facilitate appropriate treatment and more effective public health measures to mitigate disease transmission and antimicrobial resistance. Development of and improved access to reliable point-of-care diagnostics for CHIKV and other endemic pathogens should be a public health priority. Further studies are needed to confirm co-infection with DENV or other arboviruses and to explore the implications of secondary infection.
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